CD19 and neoplasm: While initial CAR-T cell therapies targeted antigens like CD19 for blood cancers, the limited presence of tumour-specific antigens, challenges with T cell infiltration, and the immunosuppressive tumour microenvironment have hindered progress for solid tumours [146,147,148].